Consider prescribing DUPIXENT for your patients with inadequately controlled severe asthma


DUPIXENT is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with Type 2 inflammation characterised by raised blood eosinophils (EOS) and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with high-dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment1

DUPIXENT is a fully human monoclonal antibody that binds specifically to the IL-4Rα subunit and inhibits IL-4 and IL-13 signalling1

The impact of severe asthma can differ from person to person2

  • Illustrative patient profiles. Not actual patients

    JULIE

    Clinical profile

    35 years old

    Severe asthma

    ≥5 annual exacerbations

    Current treatment: daily high-dose inhaled corticosteroid (ICS) plus long-acting ß2-agonist (LABA)

    Blood EOS level

    Total IgE

    Baseline FeNO

    Lung function (FEV1)

    150 cells/µL

    35 IU/mL

    35 ppb

    60%

     

  • Illustrative patient profiles. Not actual patients

    JULIE

    Impact

      I am fed up with taking so many medicines with no improvement  

    Frequent absences from work stopping her from progressing her career

    Fed up with the amount of medications she has taken for her severe asthma with little or no effect

    Finds it difficult to care for her three young children and always needs support from partner and other family members with childcare

    Tired and angry with lack of sleep as woken up numerous times at night

Patients like Julie can benefit from treatment with DUPIXENT

DUPIXENT significantly reduces asthma exacerbations, improves lung function and improves quality of life, compared to placebo3–6

DUPIXENT has a long-term safety profile observed in clinical studies of adults and adolescents1

INTRODUCING THE DUPIXENT PRE-FILLED PEN


DUPIXENT can be administered via
a pre-filled pen or a syringe1


Mode of action DUPIXENT


Have questions about how DUPIXENT works?

 

Find out more


Mode of action DUPIXENT


Have questions about how DUPIXENT works?
 


Find out more


Complexity of Type 2 inflammation

Learn more about the biomarkers involved in Type 2 inflammation.


Find out more

    A&E, accident and emergency; EOS, eosinophils; FeNO, fractional exhaled nitric oxide; FEV1forced expiratory volume in 1 second; ICS, inhaled corticosteroid; IgE, Immunoglobulin E; IL, interleukin; IU, international units; LABA, long-acting ß2-agonist; ppb, parts per billion; R, receptor.

    References

    1. Sanofi Genzyme. Dupixent Summary of Product Characteristics, September 2021.
    2. Asthma UK. What is severe asthma? Available at: https://www.asthma.org.uk/advice/severe-asthma/what-is-severe-asthma/#whatissevereasthma. Date accessed: November 2021.
    3. Bourdin A, et al. Allergy. 2021;76(1):269–280.
    4. Sanofi Data on file. REF-98937. October 2020.
    5. Rabe KF, et al. N Engl J Med. 2018;378(26):2475–2485.
    6. Bourdin A, et al. Allergy. 2021;76(1):269–280. Supplementary Appendix S1.

MAT-GB-2004974(v4.0) | Date of preparation: February 2022